Detection of Atherosclerotic Inflammation by <sup>68</sup>Ga-DOTATATE PET Compared to [<sup>18</sup>F]FDG PET Imaging.

Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH. · 2017

Read Detection of Atherosclerotic Inflammation by <sup>68</sup>Ga-DOTATATE PET Compared to [<sup>18</sup>F]FDG PET Imaging. by Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5381358.txt.

Introduction

Jason M. Tarkin led a team that tested a new scan for artery swelling in the Journal of the American College of Cardiology in 2017. Swelling inside artery plaques drives their burst, the spark of heart attacks and strokes. The standard glow scan for it is blurry: it lights all hungry cells, and heart muscle glow spills over the heart's own arteries. A sharper tracer could fix both flaws.

Their tracer locks onto a receptor found, in this work, only on the hot form of macrophage, the eater cell that stokes plaque swelling. In cut-out neck plaques, the tracer bound where those cells crowd, and its signal tracked the receptor's gene read closely. In more than forty patients, the scan split culprit arteries from quiet ones in heart and brain cases. The old scan could not match that split for heart arteries.

Catalog record

CREATORTarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5381358

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging By Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Mohammed M Chowdhury, Nichola L Figg, Aarti V Shah, Lakshi T Starks, Abel Martin-Garrido, Roido Manavaki, Emma Yu, Rhoda E Kuc, Luigi Grassi Published in: Journal of the American College of Cardiology DOI: 10.1016/j.jacc.2017.01.060 ABSTRACT Abstract Background Inflammation drives atherosclerotic plaque rupture. Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([18F]FDG PET), [18F]FDG lacks cell specificity, and coronary imaging is unreliable because of myocardial spillover. Objectives This study tested the efficacy of gallium-68-labeled DOTATATE (68Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imaging atherosclerotic inflammation. Methods We confirmed 68Ga-DOTATATE binding in macrophages and excised carotid plaques. 68Ga-DOTATATE PET imaging was compared to [18F]FDG PET imaging in 42 patients with atherosclerosis. Results Target SSTR2 gene expression occurred exclusively in “proinflammatory” M1 macrophages, specific 68Ga-DOTATATE ligand binding to SST2 receptors occurred in CD68-positive macrophage-rich carotid plaque regions, and carotid SSTR2 mRNA was highly correlated with in vivo 68Ga-DOTATATE PET signals (r = 0.89; 95% confidence interval [CI]: 0.28 to 0.99; p = 0.02). 68Ga-DOTATATE mean of maximum tissue-to-blood ratios (mTBRmax) correctly identified culprit versus nonculprit arteries in patients with acute coronary syndrome (median difference: 0.69; interquartile range [IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic attack/stroke (median difference: 0.13; IQR: 0.07 to 0.32; p = 0.003). 68Ga-DOTATATE mTBRmax predicted high-risk coronary computed tomography features (receiver operating characteristics area under the curve [ROC AUC]: 0.86; 95% CI: 0.80 to 0.92; p < 0.0001), and correlated with Framingham risk score (r = 0.53; 95% CI: 0.32 to 0.69; p <0.0001) and [18F]FDG uptake (r = 0.73; 95% CI: 0.64 to 0.81; p < 0.0001). [18F]FDG mTBRmax differentiated culprit from nonculprit carotid lesions (median difference: 0.12; IQR: 0.0 to 0.23; p = 0.008) and high-risk from lower-risk coronary arteries (ROC AUC: 0.76; 95% CI: 0.62 to 0.91; p = 0.002); however, myocardial [18F]FDG spillover rendered coronary [18F]FDG scans uninterpretable in 27 patients (64%). Coronary 68Ga-DOTATATE PET scans were readable in all patients. Conclusions We validated 68Ga-DOTATATE PET as a novel marker of atherosclerotic inflammation and confirmed that 68Ga-DOTATATE offers superior coronary imaging, excellent macrophage specificity, and better power to discriminate high-risk versus low-risk coronary lesions than [18F]FDG. (Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography [VISION]; NCT02021188) Key Words: atherosclerosis, inflammation, macrophages, molecular imaging, positron emission tomography, somatostatin receptor Abbreviations and Acronyms: ACS, acute coronary syndrome; BMI, body mass index; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; FDG, fluorodeoxyglucose; ICC, intra-class coefficient; PET, positron emission tomography; SST2, somatostatin receptor subtype-2; TBR, tissue-to-blood ratio; TBRmax, maximum tissue-to-blood ratios; TIA, transient ischemic attack Systemic inflammation triggers culprit pathogenic mechanisms, relating clinical cardiovascular disease (CVD) risk factors to atherosclerotic plaque progression and rupture (1). Quantifying vascular inflammation in atherosclerosis may reveal mechanistic pathways, allow efficacy testing of new drugs, and improve CVD risk prediction. Carotid, aortic, and peripheral arterial inflammation can be measured by fluorine-18-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) (2). However, myocardial [18F]FDG signal spillover occurs due to myocardial muscle [18F]FDG uptake, often hampering coronary artery signal quantification (3). Lack of cell specificity and the influence of hypoxia on [18F]FDG uptake within macrophages and other cells (4) are further limitations of [18F]FDG imaging. Up-regulation of the G-protein-coupled receptor somatostatin receptor subtype-2 (SST2) occurs on the surface of activated macrophages (5). Pre-clinical 6, 7 and retrospective 8, 9, 10 studies suggest that gallium-68-labeled [1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid]-d-Phe1, Tyr3-octreotate (DOTATATE), a PET ligand with high-specificity binding affinity for SST2 (11), may be superior to [18F]FDG in marking macrophage activity, particularly in the coronary arteries. However, robust evaluation of 68Ga-DOTATATE in atherosclerosis is lacking. We present a prospective clinical study evaluating 68Ga-DOTATATE PET for imaging coronary, carotid, and aortic inflammation in patients with CVD. METHODS RNA sequencing To determine target specificity of 68Ga-DOTATATE imaging in atherosclerosis, expression of the SSTR1–5 genes within in vitro- differentiated macrophage subtypes and other blood-derived cells relevant to atherosclerosis were characterized using population-based “next generation” RNA sequencing data from the European BLUEPRINT (a BLUEPRINT of haematopoietic epigenomes) project, for which all data are publicly available (12). The expression levels of glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) genes were also analyzed from the dataset; these genes encode the main glucose transporters that facilitate uptake of [18F]FDG in atherosclerotic plaques. Clinical study In the VISION (Vascular Inflammation imaging using Somatostatin receptor positron emissION tomography; NCT02021188) study, an unselected “real-world” cohort of patients with wide-ranging severity of stable (n = 18) and unstable (n = 24) CVD was prospectively enrolled from Addenbrooke’s Hospital, Cambridge, United Kingdom (Figure 1). “Stable” patients had stable angina or asymptomatic atherosclerosis and at least a 30% stenosis of a major epicardial coronary artery or an internal carotid artery. “Unstable” patients had experienced a clinical event (acute coronary syndrome [ACS] or carotid territory transient ischemic attack [TIA]/stroke) within the 3 months before imaging. Baseline cardiovascular risk factors were noted, including measurement of serum lipids and high-sensitivity C-reactive protein. Patients were older than 40 years of age and provided written, informed consent. The study protocol approved by the local research ethics committee (REC 14/EE/0019) was in accordance with the Declaration of Helsinki. [Figure: The VISION StudyPatient (A) and procedure (B) flowcharts. ∗Did not meet study criteria, n = 8; other clinical factors, n = 3; declined/cancelled, n = 49. †Coronary artery PET data excluded in ACS patients with ambiguous culprit arteries (n = 2). ‡Carotid artery PET data excluded in patients with prior carotid surgery (n = 2). §[18F]-FDG PET imaging not completed because of timing of surgery (n = 1). ‖Tissue samples excluded owing to insufficient mRNA extracted for quantitative PCR (n = 2). ¶CT scans not completed (calcium scan, n = 1; coronary angiogram, n = 5; carotid angiogram, n = 2). ACS = acute coronary syndrome; CT = computed tomography; CVD = cardiovascular disease; FDG = fluorodeoxyglucose; PCR = polymerase chain reaction; PET = positron emission tomography; TIA = transient ischemic attack; VISION = Vascular Inflammation imaging using Somatostatin receptor positron emissION tomography.] PET-CT imaging Patients underwent 68Ga-DOTATATE PET-CT and [18F]FDG PET-CT imaging, using established methods (13) for vascular PET imaging on a Discovery 690 combined PET-CT system model (GE Healthcare, Little Chalfont, United Kingdom; extended Methods are detailed in the Online Appendix). 68Ga-DOTATATE had an average radiochemical purity of 99% on quality control testing performed by the manufacturer (Mallinckrodt, St. Louis, Missouri). Patients fasted for 6 h prior to [18F]FDG imaging; capillary blood glucose concentration was confirmed as <7.0 mmol/l in nondiabetic patients prior to scanning. Patients with diabetes mellitus were instructed to take their antidiabetic medications as usual prior to [18F]FDG scanning but to hold insulin within 4 h of the scan; if glucose level was >11.0 mmol/l, the scan was rescheduled according to our standard clinical practice. Insulin was not administered to any patient prior to [18F]FDG PET imaging. The mean injected dose of 68Ga-DOTATATE was 147.8 ± 31.6 MBq and 248.1 ± 22.3 MBq for [18F]FDG. Electrocardiography (ECG)-gated CT coronary angiography plus calcium scanning and carotid angiography were also performed. Image analysis Static PET images were reconstructed using 3-dimensional (3D) iterative time-of-flight ordered-subset expectation maximization

Read the complete text